Awards...



CLINGENUITY NAMED COOL VENDOR

Certara, a biosimulation technology-enabled drug development consultancy and its Clin-Genuity company, was named a Cool Vendor in Gartner's 2015 Life Sciences report. ClinGenuity was acquired by Synchrogenix, Certara's regulatory writing company, in January 2015. Synchrogenix uses an Al/natural language recognition and processing engine to identify individual words, parts of speech, word combinations, and phrase combinations.

PAREXEL IS RECOGNIZED FOR DIGITAL COMMUNICATIONS

Parexel has been awarded a 2015 Gold Quill
Merit Award from the International Association of Business Communicators (IABC). The award recognized the company for developing creative, engaging digital communications with messaging that effectively reaches target audiences. In a separate recognition, Parexel's Drew Garty, senior director, product management, was named the 2015 Clinical Innovator of the Year by Partnerships in Clinical Trials. The honor recognizes his leadership of the product development team for the company's Perceptive MyTrials solution.

PHYSICIANS INTERACTIVE HONORED FOR COMMITMENT TO HEALTHCARE

Chairman and CEO of Physicians Interactive Donato Tramuto received an honorary doctorate of humane letters from the

University of Massachusetts Lowell at its commencement ceremony on Saturday, May 16. Mr. Tramuto was recognized for his commitment to healthcare access and life-sciences thought leadership. He is also the founder of lth eVillages a popprofit organization in

leadership. He is also the founder of Health eVillages, a nonprofit organization in partnership with Robert F. Kennedy Human Rights that brings state-of-the-art mobile technology with embedded, trusted medical content to the most remote areas of the world. Mr. Tramuto has also been named as a PharmaVOICE 100 and Red Jacket honoree.

RISING STAR JENNIFER WELLMAN Spark Therapeutics' named Jennifer Wellman.

co-founder and head of regulatory strategy, as a 2015 Healthcare Businesswomen's Association Rising Star. Her strong scientific background in gene therapy and business instincts make her an asset to the overall success of the organization.

Genentech Supports NEW STEM INITIATIVE



Students from Alta Loma Middle School compete in the "spinoff" science challenge as they use a colander to simulate the separation properties of a centrifuge. This activity was part of the series of Helix Cup school science challenges in late April that led up to the final challenge on Genentech's campus on May 4.

Genentech has launched Futurelab, a collaborative program with the South San Francisco Unified School District to support science, technology, engineering and mathematics education. Futurelab builds on Genentech's long-standing commitment to science education and seeks to make a difference in the lives of local students, empower teachers, and inspire employees. Through the program, South

San Francisco students at every grade level will have opportunities to engage in STEM. Futurelab includes plans for the creation of Science Garage, a state-of-the-art biotech classroom space at South San Francisco High School. The Genentech Foundation intends to fund the construction of a 8,000 square-foot, stand-alone building, with a proposed completion date of 2017.

PTC Therapeutics LAUNCHES GRANT AWARD PROGRAM



PTC Therapeutics has launched STRIVE (Strategies to Realize Innovation, Vision and Empowerment), an awards program aimed at providing funds to patient advocacy organizations to develop unique and collaborative programs that will make meaningful contributions


to the rare disease community. The program, in its inaugural year, will focus on Duchenne muscular dystrophy (DMD).

"From the time PTC was founded, patient organizations have been valuable partners to us and have played important roles in our research and development programs. We are excited to support these groups and enable them to use their creativity and experience to raise awareness and make a difference

Combination Products Expected in Oncology

Over the next five years, combinations of targeted and immune-oncology agents will account for many NME launches and line extensions.

Year No. of Projected Launches



Source: CenterWatch, FDA, clinicaltrials.gov, IMS R&D LifeCycle, IMSCG Analysis

for the DMD community," says Stuart Peltz, Ph.D., CEO of PTC Therapeutics.

walsh@pharmavoice.c

PharmaLinx LLC. Rights do not include promotional use.

ribution or printing rights,



GSK Asthma Care Program ADDRESSES HEALTH DISPARITIES

New data from a school asthma management program, Building Bridges for Asthma Care, show a significant decrease in school absenteeism among children with asthma from inner-city schools who were enrolled in the program. Absences dropped 11.75% among children enrolled in Building Bridges, compared with an increase of 8.48% in children with asthma not in the program.

Building Bridges is a school-based program

PHARMACEUTICAL

RESEARCH AND

MANUFACTURERS OF

AMERICA'S (PHRMA)

MEMBER COMPANIES INVESTED

AN ESTIMATED \$51.2 BILLION

LAST YEAR IN THE RESEARCH AND

DEVELOPMENT (R&D) OF NEW

INNOVATIVE TREATMENTS

AND CURES.

designed to empower nurses in participating elementary schools to ensure that asthmatic children are identified and provided care according to the National Institute of Health's clinical treatment guidelines. It is a collaboration between GlaxoSmithKline, Children's Hospital Colorado, Connecticut Children's Medical Center, National Jewish Health, Rho and the public school systems in Denver and Hartford.

Opiate Users AT RISK FOR MISUSE

use and account for 92% of an employer's overall opiate healthcare costs, according to a recent anal-

Seven percent of people who have been prescribed an opioid in the past four years have two or more causes for concern with chronic use. The causes for concern are: 10 or more opioid prescriptions, or a prescribed supply for 120 days or more, or a week or more of overlapping opioid or benzodiazepine prescriptions.

of Healthentic.

About 13% of opiate users are at risk for chronic ysis from Healthentic.

"Our hope is this analysis provides further insight into the societal and financial issue of prescription painkillers, and helps employers take strides in alleviating the problem to ensure the well-being of their people," says Jeff O'Mara, CEO

Innovation Corner

PROJECT DATA SPHERE AND SAGE BIONETWORKS LAUNCH PROSTATE **CANCER CHALLENGE**

Project Data Sphere and Sage Bionetworks, in collaboration with the multi-institutional DREAM Challenges Initiative, have launched Prostate Cancer DREAM Challenge to improve prediction of survival, disease progression, and treatment toxicity in advanced disease.

The challenge marries crowdsourcing with data sharing, paving a new way to tackle key research questions about metastatic castration-resistant prostate cancer (mCRPC),

an advanced form of the disease with poor outcomes. The challenge calls upon the cancer research and computational biology community to find solutions to key unanswered questions about mCRPC and explore innovative research and modeling approaches. The DREAM Challenges Initiative brings the proven research challenge methodology, with a track record of more than 32 successful scientific research challenges.

PHARMAVOICE.COM

EBOOKS

» Your Patients Are Here: Where to **Recruit and How to Retain Highly Engaged Patients**

Provided by: DAC Patient Recruitment

» The Drug Development Journey **Provided by: PAREXEL**

PODCAST

» Partnering with Patients: A Game-changer for Patient Advocacy **Groups and Pharma**

Provided By: inVentiv Health

WHITE PAPERS

- » Putting Volunteers First: What Every **Clinical Team Should Consider Before Developing the Next Protocol Provided Provided By:** Fisher Clinical Services
- » The New Partnership Paradigm: **What Patient Advocates Seek from Pharmaceutical Partners** Provided By: inVentiv Health

» Advancing Pharmaceutical Sales **Models with Innovative Tele-sales**

Provided By: Tunstall Americas

UPCOMING WEBINARS

» Structured Content Management: A Sanofi Case Study

Date: June 3, 2015

Sponsored by: DitaExchange

ON-DEMAND WEBINARS:

» Vascular Health Profiling Proactively **Measures MACE Risk**

Sponsored by: CytoVas

» Easy Implementation of a Clinical **Data Repository: A Business Critical Platform**

Sponsored by: eClinical Solutions

